Stocktoria
PROCYON CORP PCYN
PROCYON CORP (PCYN) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2024 revenue was $5.0M at a -6.8% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
Beneish M-score: -3.1 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Manufacturing · percentile among 1906 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.498 |
| Retained earnings / assets | -0.727 |
| EBIT / assets | -0.072 |
| Equity / liabilities | 2.494 |
Sector peers · similar-size Manufacturing companies
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PCYN | PROCYON CORP | 3/9 | 3.03 | — | — |
| ENSC | Ensysce Biosciences, Inc. | — | — | — | — |
| ABEO | ABEONA THERAPEUTICS INC. | 4/9 | -5.75 | 4.5 | — |
| CPHI | CHINA PHARMA HOLDINGS, INC. | 4/9 | -3.85 | — | — |
| ATAI | AtaiBeckley Inc. | 4/9 | — | — | — |
| CRVO | CervoMed Inc. | 1/9 | -12.9 | — | — |
| KRRO | Korro Bio, Inc. | 2/9 | -13.3 | — | — |
FAQ
Is PCYN financially healthy?
PROCYON CORP's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does PCYN pay a dividend?
No, PROCYON CORP does not currently pay a dividend.
How profitable is PCYN?
In FY2024, PROCYON CORP had a net margin of -6.8% and a return on equity of -14.9%.
Source: SEC EDGAR filings · CIK 0000812306 · US · as of 2024-06-30. facts plus Stocktoria's own computed scores — not investment advice.